Leptin affects body weight and reproduction mainly via receptors in the central nervous system. Different isoforms of the leptin receptor (leptin-R) exist, including a long isoform (leptin-RL) with signalling capacity and short isoforms (leptin-RS) with unknown function. The aim of this study was to examine leptin-R gene expression in different regions of the brain under conditions with altered body weight, in the female rat, including ovariectomy (OVX), oestradiol (E2) treatment, fasting and a genetic model of obesity (Zucker fa/fa). Leptin-R gene expression was analysed by in situ hybridization using probes recognizing all receptor isoforms (leptin-R) or specifically leptin-RL. Transcripts recognized by the leptin-R probe were abundant in the choroid plexus (CP), arcuate nucleus (ARC), ventromedial nucleus (VMN), thalamus (TH) and piriform cortex (PC). Leptin-RL transcripts were detected in the ARC, VMN, TH and PC but not in the CP. Although no sex difference was observed, leptin-R gene expression was reduced by E2 administration and increased by OVX. Administration of E2 reduced leptin-RL gene expression in the ARC and VMN but did not alter the expression in the TH or PC. OVX had no effect on the expression of leptin-RL mRNA. Fasting also caused a differential regulation of leptin-R mRNAs, with an increase in abundance of leptin-RL transcripts in the TH despite a decrease in leptin-R in this area. Obese Zucker rats had a similar pattern of expression with an increased expression of leptin-RL transcripts in all brain areas analysed and a decrease in leptin-R gene expression. These results demonstrate a differential regulation of leptin-RL and leptin-RS which could provide a mechanism for regulating access to, and sensitivity of, discrete regions of the brain for circulating leptin. We suggest that fasting and E2 alter the balance between leptin-RL and leptin-RS and that this could increase tissue sensitivity to leptin.

Keywords:
Leptin receptor, Fasting, Zucker rats, In situ hybridization, Gonadal steroids, Arcuate nucleus, Ventromedial nucleus, Choroid plexus, Cortex
1.
Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM: Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425–432.
2.
Coleman DL: Effects of parabiosis of obese with diabetes and normal mice. Diabetologia 1973;9:294–298.
3.
Caro JF, Sinha MK, Kolaczynski JW, Zhang PL, Considine RV: Leptin: The tale of an obesity gene. Diabetes 1996;45:1455–1462.
4.
Flier JS: Leptin expression and action: New experimental paradigms. Proc Natl Acad Sci USA 1997;94:4242–4245.
5.
Campfield LA, Smith FJ, Burn P: The ob protein (leptin) pathway – A link between adipose tissue mass and central neural networks. Horm Metab Res 1996;28:619–632.
6.
Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos-Flier E, Flier JS: Role of leptin in the neuroendocrine response to fasting. Nature 1996;382:250–252.
7.
Chehab FF, Lim ME, Lu R: Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. Nat Genet 1996;12:318–320.
8.
Chehab FF, Mounzih K, Lu R, Lim ME: Early onset of reproductive function in normal female mice treated with leptin. Science 1997;275:88–90.
9.
Ahima RS, Dushay J, Flier SN, Prabakaran D, Flier JS: Leptin accelerates the onset of puberty in normal female mice. J Clin Invest 1997;99:391–395.
10.
Cheung CC, Thornton JE, Kuijper JL, Weigle DS, Clifton DK, Steiner RA: Leptin is a metabolic gate for the onset of puberty in the female rat. Endocrinology 1997;138:855–858.
11.
Tartaglia LA: The leptin receptor. J Biol Chem 1997;272:6093–6096.
12.
Kishimoto T, Taga T, Akira S: Cytokine signal transduction. Cell 1994;76:253–262.
13.
Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, Devos R, Richards GJ, Campfield LA, Clark FT, Deeds J, Muir C, Sanker S, Moriarty A, Moore KJ, Smutko JS, Mays GG, Woolf EA, Monroe CA, Tepper RI: Identification and expression cloning of a leptin receptor, OB-R. Cell 1995;83:1263–1271.
14.
Vaisse C, Halaas JL, Horvath CM, Darnell JE Jr, Stoffel M, Friedman JM: Leptin activation of Stat3 in the hypothalamus of wild-type and ob/ob mice but not db/db mice. Nat Genet 1996;14:95–97.
15.
White DW, Kuropatwinski KK, Devos R, Baumann H, Tartaglia LA: Leptin receptor (OB-R) signaling: Cytoplasmic domain mutational analysis and evidence for receptor homo-oligomerization. J Biol Chem 1997;272:4065–4071.
16.
Banks WA, Kastin AJ, Huang W, Jaspan JB, Maness LM: Leptin enters the brain by a saturable system independent of insulin. Peptides 1996;17:305–311.
17.
Murakami T, Yamashita T, Iida M, Kuwajima M, Shima K: A short form of leptin receptor performs signal transduction. Biochem Biophys Res Commun 1997;231:26–29.
18.
Wu-Peng XS, Chua SC Jr, Okada N, Liu S-M, Nicolson M, Leibel RL: Phenotype of the obese Koletsky (f) rat due to tyr763stop mutation in the extracellular domain of the leptin receptor (lepr): Evidence for deficient plasma-to-CSF transport of leptin in both the Zucker and Koletsky obese rat. Diabetes 1997;46:513–518.
19.
Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, Lakey ND, Culpepper J, Moore KJ, Breitbart RE, Duyk GM, Tepper RI, Morgenstern JP: Evidence that the diabetes gene encodes the leptin receptor: Identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996;84:491–495.
20.
Chua SC Jr, Chung WK, Wu-Peng XS, Zhang Y, Liu S-M, Tartaglia L, Leibel RL: Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science 1996;271:994–996.
21.
Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156–159.
22.
Bennett PA, Levy A, Sophokleous S, Robinson IC, Lightman SL: Hypothalamic GH receptor gene expression in the rat: Effects of altered GH status. J Endocrinol 1995;147:225–234.
23.
Mercer JG, Hoggard N, Williams LM, Lawrence CB, Hannah LT, Trayhurn P: Localization of leptin receptor mRNA and the long form splice variant (Ob-Rb) in mouse hypothalamus and adjacent brain regions by in situ hybridization. FEBS Lett 1996;387:113–116.
24.
Phillips MS, Liu Q, Hammond HA, Dugan V, Hey PJ, Caskey CT, Hess JF: Leptin receptor missense mutation in the fatty Zucker rat. Nat Genet 1996;13:18–19.
25.
Takaya K, Ogawa Y, Isse N, Okazaki T, Satoh N, Masuzaki H, Mori K, Tamura N, Hosoda K, Nakao K: Molecular cloning of rat leptin receptor isoform complementary DNAs – Identification of a missense mutation in Zucker fatty (fa/fa) rats. Biochem Biophys Res Commun 1996;225:75–83.
26.
Ghilardi N, Skoda RC: The leptin receptor activates janus kinase 2 and signals for proliferation in a factor-dependent cell line. Mol Endocrinol 1997;11:393–399.
27.
Schwartz MW, Seeley RJ, Campfield LA, Burn P, Baskin DG: Identification of targets of leptin action in rat hypothalamus. J Clin Invest 1996;98:1101–1106.
28.
Erickson JC, Hollopeter G, Palmiter RD: Attenuation of the obesity syndrome of ob/ob mice by the loss of neuropeptide Y. Science 1996;274:1704–1707.
29.
Le Magnen J: Olfaction and nutrition; in Lloyd M Beidler (ed): Handbook of Sensory Physiology. Berlin, Springer, 1971 vol IV, pp 465–482.
30.
Powell TPS, Cowan WM, Raisman G: The central olfactory connexions. J Anat 1965;99:791–813.
31.
Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P: Recombinant mouse OB protein: Evidence for a peripheral signal linking adiposity and central neural networks. Science 1995;269:546–549.
32.
Starr MS, Summerhayes M: Role of ventromedial nucleus of the thalamus in motor behaviour. II. Effects of lesions. Neuroscience 1983;10:1171–1183.
33.
Starr MS, Summerhayes M: Role of ventromedial nucleus of the thalamus in motor behaviour. I. Effects of focal injections of drugs. Neuroscience 1983;10:1157–1169.
34.
Caro JF, Kolaczynski JW, Nyce MR, Ohannesian JP, Opentanova I, Goldman WH, Lynn RB, Zhang PL, Sinha MK, Considine RV: Decreased cerebrospinal-fluid/serum leptin ratio in obesity: A possible mechanism for leptin resistance. Lancet 1996;348:159–161.
35.
Schwartz MW, Peskind E, Raskind M, Boyko EJ, Porte D Jr: Cerebrospinal fluid leptin levels: Relationship to plasma levels and to adiposity in humans. Nat Med 1996;2:589–593.
36.
Van Heek M, Compton DS, France CF, Tedesco RP, Fawzi AB, Graziano MP, Sybertz EJ, Strader CD, Davis HR: Diet induced obese mice develop peripheral, but not central, resistance to leptin. J Clin Invest 1997;99:385–390.
37.
Golden PL, Maccagnan TJ, Pardridge WM: Human blood-brain barrier leptin receptor: Binding and endocytosis in isolated human brain microvessels. J Clin Invest 1997;99:14–18.
38.
Richter CP, Uhlenhuth EH: Comparison of the effects of gonadectomy on spontaneous activity of wild and domesticated Norway rats. Endocrinology 1954;54:323–337.
39.
Mook DG, Kenney NJ, Roberts S, Nussbaum AI, Rodier WI: Ovarian-adrenal interactions in regulation of body weight by female rats. J Comp Physiol Psychol 1972;81:198–211.
40.
Mercer JG, Moar KM, Rayner DV, Trayhurn P, Hoggard N: Regulation of leptin receptor and NPY gene expression in hypothalamus of leptin treated obese (ob/ob) and cold exposed lean mice. FEBS Lett 1997;402:185–188.
41.
Charlton HM: Mouse mutants as models in endocrine research. Q J Exp Physiol 1984;69:655–676.
42.
Koletsky RJ, Ernsberger P: Phenotypic characterization of a genetically obese and hypertensive rat strain: SHROB/Kol. Rat Genome 1996;2:10–22.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.